dUTPase inhibition augments replication defects of 5-Fluorouracil
Metrics: PDF 1426 views | HTML 2041 views | ?
Anna Hagenkort1,*, Cynthia B.J. Paulin1,*, Matthieu Desroses1,*, Antonio Sarno2, Elisée Wiita1, Oliver Mortusewicz1, Tobias Koolmeister1, Olga Loseva1, Ann-Sofie Jemth1, Ingrid Almlöf1, Evert Homan1, Thomas Lundbäck3, Anna-Lena Gustavsson3, Martin Scobie1, Thomas Helleday1
1Division of Translational Medicine and Chemical Biology, Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
2Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
3Chemical Biology Consortium Sweden, Division of Translational Medicine and Chemical Biology, Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
*These authors have contributed equally to this work
Thomas Helleday, email: firstname.lastname@example.org
Keywords: dUTPase, 5-Fluorouracil, DNA replication, combination therapy
Received: July 07, 2016 Accepted: February 06, 2017 Published: February 28, 2017
The antimetabolite 5-Fluorouracil (5-FU) is used in the treatment of various forms of cancer and has a complex mode of action. Despite 6 decades in clinical application the contribution of 5-FdUTP and dUTP [(5-F)dUTP] and 5-FUTP misincorporation into DNA and RNA respectively, for 5-FU-induced toxicity is still under debate.
This study investigates DNA replication defects induced by 5-FU treatment and how (5-F)dUTP accumulation contributes to this effect. We reveal that 5-FU treatment leads to extensive problems in DNA replication fork progression, causing accumulation of cells in S-phase, DNA damage and ultimately cell death. Interestingly, these effects can be reinforced by either depletion or inhibition of the deoxyuridine triphosphatase (dUTPase, also known as DUT), highlighting the importance of (5-F)dUTP accumulation for cytotoxicity.
With this study, we not only extend the current understanding of the mechanism of action of 5-FU, but also contribute to the characterization of dUTPase inhibitors. We demonstrate that pharmacological inhibition of dUTPase is a promising approach that may improve the efficacy of 5-FU treatment in the clinic.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.